Swiss drugmaker Roche Holding AG (ROG.VX) had obtained a global license from U.S biotech group Genzyme (GENZ.O). this means they develop a new method of test for lung cancer cell mutations.
The aim is to provide a simple tool that will quickly identify epidermal growth-factor receptor (EGFR) activating mutations, said by Daniel ODay, head of Roches diagnostic division. So they can enhance physicians ability to customize the use of Tarceva for people with advanced NSCLC. A pill will be taken once a day for treating lung and pancreatic cancer, in order to improve administration of its drug Tarceva.
A companion test to identify people with non-small lung cell cancer (NSCLC) will be developed in collaboration with OSI Pharmaceuticals.
The European Medicines Agency has previously approved Roche to extend the current label for Tarceva, include treatment of patients with advanced NSCLC that exhibit EGFR-activating mutations. The EU and U.S. currently approved the drug is used in second-line treatment and maintenance for advanced or metastatic NSCLC, both with EGFR-activating mutations and without EGFR-activating mutations. The drug is singly approved as part of combination therapy for later period pancreatic cancer.
Roche (Roche) company, is a multinational pharmaceutical R & D manufacturers, whose headquartered is in Basel, Switzerland,
Roche, which is co-founded by the Fritz Hoffmann La Roche (Roche family) in 1896, is world-famous for variety of Vitamins and derivatives. 1957 it Introduced classification mechanism of Benzene into diazonium class of sedative drugs (for example, the stability and Rohypnol and other common sedative). Many registered trademark drugs of acne such as Accutane and Roaccutane produced by Roche, are the first choice for the treatment of malignant acne drug in the market. It also produces several tests and inhibited drugs of HIV. In 1992 it bought a major polymerase chain reaction technology patents. It is also the manufacturer of several anti-cancer drugs. In the 21st century ,Roche got significant growth in the oncology market share. As it developed Herceptin (Herceptin), Rituximab (Mab Thera) and bevacizumab (Avastin) which are the representative of the monoclonal antibody targeted cancer therapy drugs, In 2000 and 2005 sales of Roche oncology surged from 1.6 billion to 8.3 billion ,accounted for 25% of the global oncology market.